SKLB1002featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:401980
CAS#:1225451-84-2
Description:SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation. Western blot analysis was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src. In vivo zebrafish model experiments showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos. SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.
Price and Availability
SKLB1002, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 401980Name: SKLB1002CAS#: 1225451-84-2Chemical Formula: C13H12N4O2S2Exact Mass: 320.04017Molecular Weight: 320.39Elemental Analysis: C, 48.73; H, 3.78; N, 17.49; O, 9.99; S, 20.02
Synonym:SKLB1002; SKLB 1002; SKLB1002.
IUPAC/Chemical Name:2-((6,7-dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole
InChi Key:RQVGFDBMONQTBC-UHFFFAOYSA-N
InChi Code:InChI=1S/C13H12N4O2S2/c1-7-16-17-13(20-7)21-12-8-4-10(18-2)11(19-3)5-9(8)14-6-15-12/h4-6H,1-3H3
SMILES Code:CC1=NN=C(SC2=C3C=C(OC)C(OC)=CC3=NC=N2)S1
Technical Data
Additional Information
References
1: Nie W, Ma XL, Sang YX, Li YL, Gao X, Xu GC, ShenGB, Shi HS, Liu XX, Wang FT, Wei YQ. Synergic antitumor effect ofSKLB1002 and local hyperthermia in 4T1 and CT26. Clin Exp Med. 2012 Dec21. [Epub ahead of print] PubMed PMID: 23263406.
2: Shen G, Li Y, Du T, Shi G, Dai L, Chen X, Zheng R, Li W, Su X, ZhangS, Wei Y, Yang S, Deng H. SKLB1002, a novel inhibitor of VEGF receptor 2signaling, induces vascular normalization to improve systemicallyadministered chemotherapy efficacy. Neoplasma. 2012;59(5):486-93. doi:10.4149/neo_2012_062. PubMed PMID: 22668017.
3: Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S,Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L,Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y. SKLB1002, a novel potentinhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumorgrowth in vivo. Clin Cancer Res. 2011 Jul 1;17(13):4439-50. doi:10.1158/1078-0432.CCR-10-3109. Epub 2011 May 27. PubMed PMID: 21622720.
